Cannabis Report
Home > Boards > US OTC > Medical - Equipment >

Imagin Medical Inc. (IMEXF)

IMEXF RSS Feed
Add IMEXF Price Alert      Hide Sticky   Hide Intro
Moderator: SO75
Search This Board: 
Last Post: 6/22/2018 7:37:17 PM - Followers: 16 - Board type: Free - Posts Today: 3





 

 

Overview

 Imagin Medical is a medical imaging company
Imagin Medical will establish a new standard of care in the detection and removal of cancer using endoscopes by commercializing an advanced, proprietary and patented imaging technology
 Initially targeting bladder cancer 
 Thereafter expanding to all minimally invasive surgical (MIS) procedures where endoscopes are used
 

Benefits of Minimally Invasive Surgery (MIS)

• Performed using tiny holes or incisions (less muscle cut)
• Reduced pain, smaller / no scarring
• Quicker recovery, shorter hospital stay, less expensive
• Minimally invasive surgeries performed using endoscopes














 


Endoscopic Primer

• Endoscopic means “to look inside”
• Endoscope – a medical device with attached light used to look inside organs
• Endoscopy performed when other tools, such as an MRI, X-ray, or CT scan, are inappropriate
• Endoscopies commonly performed to diagnose cancer, take tissue samples for biopsies, and to remove cancer
• Different medical specialties use different types of endoscopes
• Cystoscopes, Bronchoscopes, Gastroscopes, Laparoscopes
   










 

Endoscopic Market
 
 $46B growing global endoscopy market
 $1B is spent annually in US alone on bladder cancer surveillance
 Bladder cancer is 3rd most common in men and 6th most common in US overall with recurrence rate of 40 – 70% making it the most expensive cancer to treat over the lifetime of a patient
 4 million estimated urology endoscopy procedures performed each year targeting bladder cancer
 Imagin’s disruptive imaging technology squarely addresses limitations in:
• Endoscopies targeting bladder cancer (cystoscopies)
• Endoscopies targeting many other cancers


 


 

Endoscope Limitations - White Light

• Current endoscopes use “white light” (or visible light) that has been the gold standard for decades
• Highly effective for detecting protruding cancerous tumors
• Limitations of white light:
• Tumors that are flat may look the same as normal tissue
• Not effective in visualizing the edges of the tumor
• Inability to illuminate tumors beneath skin surface


 

Endoscope Limitations - Blue Light

• Blue light cystoscopes (white light with blue filter) used with contrasting agents induce fluorescence and improve ability to detect flat cancers and visualize edges
• Drawbacks of existing blue light technology:
• Requires one hour for the agent to be absorbed by bladder
• Surgeon must manually “switch” between white light and blue light to see tumor area
• Repeated usage of imaging agent causes adverse side-effects (FDA limits use of contrast agents to one-time use per patient)
 

 
Disruptive Technology - Endoscopes with i/Blue Imaging System

• Significantly reduced prep time with bladder absorption in less than 15 minutes vs. one hour
• Optics 100,000 X more sensitive
• Simultaneous acquisition of differing images
• No switching back and forth
• Blends the white light and fluorescence images into one
• Enables the surgeon to better visualize and resect the cancer
• This advancement makes i/Blue technology practical, not only for the O.R. but also potentially for the physicians’ office
• Adapts seamlessly to most types of endoscopes on the market
 
Future Development - i/Vision Imaging System

• Incorporates multiple illumination sources in one system
• Accommodates the most commonly used fluorescing contrast agents, i.e., such as those based on the emission of Protoporphyrin IX (PpIX) and Indocyanine green (ICG)
• This instrument enables expansion into multiple endoscopic procedures such as laparoscopic (general and gynecology), colorectal, thoracic and gastroenterology procedures related to cancer and non-cancerous conditions
• Like i/Blue, blends two images into one, adapts to most endoscopes, and orders of magnitude more sensitive
 
Future Development - i/Red Imaging System

• Requires no contrasting agents - uses the fluorescence produced by the body and tumor itself
• Contrast between normal and cancer tissue is potentially related to difference in porphyrin content within the cells
• Dramatically expands the market to endoscopic procedures where imaging agents cannot be practically administered
• Like i/Blue, blends two images into one, adapts to most endoscopes, orders of magnitude more sensitive
 
Intellectual Property

• Underpinning company’s technology are three issued patents and two pending patent applications on technology related to near-infrared spectroscopic imaging for cancer and other medical applications obtained, under exclusive license, from Lawrence Livermore National Security, LLC
• Aim of licensing agreement is to commercialize the technology invented by Dr. Stavros Demos, a key advisor to the company


 
Product Development Roadmap


 
Why Invest in Imagin Medical?

• Key investment risks removed, high investment return potential
• Disruptive cutting edge imaging technology will dramatically reduce bladder cancer recurrence rates addressing $1B growing global market
• Limited R&D risks as concept is proven – this is an execution play
• Experienced medical device management team that has done it before
• Management in medical device field for over 30 years
• Worked together in previous companies
• High-margin product with strong clinical and economic advantages
• Commercial launch expected in 2018 with positive operating cash flows
• Strong acquisition market
• Most medical device companies grow by acquisition, not organically
• Company expected to have significant value with multiple liquidity options
 

 
Number of Shares Outstanding as at August 31, 2017:                50,068,739
 
Shares Subject to Resale Restrictions    
1) Shares subject to escrow (1,725,000 released every 6 months - Feb 9 & Aug 9) 5,175,000  
2) Performance shares 5,000,000  
Total Shares Subject to Resale Restrictions   10,175,000
Total Tradeable Float   39,893,739
Total Shares Outstanding   50,068,739

Number of Warrants Outstanding as at August 31, 2017:             25,005,064
 
Warrants Outstanding    
Feb 2016 Private Placement Strike @ 0.35 - expire Feb 9, 2018 7,007,413
Q4/2016 PP - Tranche 1 Strike @ 0.12 / 0.16 - expire Oct 20, 2018 5,111,300
Q4/2016 PP - Tranche 2 Strike @ 0.12 / 0.16 - expire Dec 9, 2018 3,980,565
Warrants from BSS acquisition Strike @ 0.15 - expire Feb 9, 2019 8,905,786
Total Warrants Outstanding   25,005,064

Number of Options Outstanding as at August 31, 2017:                3,350,000
 
 Management Options Outstanding    
Tranche 1 Strike @ 0.15 3,350,000
Total Options Outstanding   3,350,000
 
Various Company Links

Company Web Site
Corporate Presentation (10/2/2017)

CSE Web Site for Imagin Medical
SEDAR Web Site for Imagin Medical

Listing Statement CSE - February 16, 2016

Share Issuance - February 9, 2016
Share Issuance - August 22, 2016
Share Issuance - October 21, 2016
Share Issuance - December 13, 2016
Convertible Debt Issuance - March 3, 2017
Share Issuance - October 4, 2017

Option Grant - June 30, 2016
Option Grant - December 19, 2016
Option Grant - April 10, 2017

Information Circular - October 31, 2016

Monthly CSE Filings (CSE Form 7)
 
  2016 2017
January N/A Link
February Link Link
March Link Link
April Link Link
May Link Link
June Link Link
July Link Link
August Link Link
September Link  
October Link  
November Link  
December Link  

Financial Statements (FS) & Management Discussion and Analyses (MD&A)
 
      2015 2016 2017
Q2 Quarter Ended March 31 FS   Link Link
MD&A   Link Link
Q3 Quarter Ended June 30 FS   Link Link
MD&A   Link Link
Q4 Quarter Ended September 30 FS Link Link  
MD&A Link Link  
Q1 Quarter Ended December 31 FS Link Link  
MD&A Link Link  

 

 
Cannabis Report
IMEXF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#579  Sticky Note Capital Ideas Episode 25 SO75 03/14/18 01:40:25 PM
#842   Waiting for the big news. Real confirmation Imagin 7Card 06/22/18 07:37:17 PM
#841   Cut and paste resulted in the ?? after Neverending 06/22/18 09:12:19 AM
#840   Should see a steady price decline from here Neverending 06/22/18 08:53:46 AM
#839   Until new information emerges, it seems there is IMeasy 06/21/18 11:45:21 PM
#838   Always waiting on news, nothing new here lol... MSU 06/21/18 08:47:41 PM
#837   starting to look like a pennyland flim-flam operation. Neverending 06/21/18 07:11:16 PM
#836   Final Post: AMG 06/21/18 07:00:30 PM
#835   You received a twitter that big news was AMG 06/21/18 06:39:18 PM
#834   It seems logical to me that management would IMeasy 06/21/18 06:10:58 PM
#833   Maybe the "big news"fell through? Possibly the company Neverending 06/21/18 05:27:59 PM
#832   The market did not like the news! Management Neverending 06/21/18 05:07:32 PM
#831   I sent Jim an email. I had a AMG 06/21/18 02:25:49 PM
#830   To Imagin Management: A Wishing Well AMG 06/21/18 02:07:46 PM
#829   You got the "big news"! A PR firm! Neverending 06/21/18 02:00:52 PM
#828   More like 6 trading days left, buy they AMG 06/21/18 01:53:14 PM
#827   Welcome In The Summer Solstice AMG 06/21/18 01:39:49 PM
#826   Well, they have 9 days left in the 7Card 06/21/18 01:33:57 PM
#825   So they screw common shareholders in the process AMG 06/21/18 01:07:57 PM
#824   May not be THE news. Bringing on Kilmer IMeasy 06/21/18 12:45:51 PM
#823   May not be THE news. Bringing on Kilmer IMeasy 06/21/18 12:45:51 PM
#822   Big news they say! A PR FIRM! PATHETIC. Neverending 06/21/18 12:28:56 PM
#821   Who cares? That board is full of numbnuts AMG 06/21/18 12:11:38 PM
#820   Accross the street at the other board, stockhxxse, IMeasy 06/21/18 11:14:28 AM
#819   So their goal was to release "news" before AMG 06/21/18 10:32:57 AM
#818   This is not the news. Another one is SO75 06/21/18 10:29:14 AM
#817   You're completely missing the point. You got duped AMG 06/21/18 10:22:27 AM
#816   If this is the only news I'm with SO75 06/21/18 10:18:52 AM
#815   Shareholders were dangled on a Twitter feed for AMG 06/21/18 10:02:30 AM
#814   If the upcoming announcement is a big "nothing IMeasy 06/19/18 04:46:49 PM
#813   $6300 To $7000 US. That is the cash IMeasy 06/19/18 04:38:48 PM
#812   The real market price is what it is AMG 06/19/18 03:57:59 PM
#811   US Volume. Ameritrade reports only 35,000 shares sold IMeasy 06/19/18 03:25:33 PM
#810   Imagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is SO75 06/19/18 10:45:33 AM
#809   Imagin needs to get on with whatever news AMG 06/19/18 08:39:12 AM
#808   +1 Endless Russian Autobot AMG 06/16/18 10:38:05 AM
#807   7 card. Thanks for your comments. I IMeasy 06/16/18 10:22:09 AM
#806   2 paid promoters appear to run this board Neverending 06/16/18 08:36:29 AM
#805   Were All In This Fight Together And Our AMG 06/16/18 06:45:45 AM
#804   Sincerely sorry about your news. I hope she 7Card 06/16/18 02:00:14 AM
#803   Flat cancers. I posted weeks ago about IMeasy 06/15/18 02:54:25 PM
#802   Never, so you really think well known Urologist's 7Card 06/15/18 01:23:38 AM
#801   Unfortunately, I just read your threads. IMO not AMG 06/14/18 09:22:03 PM
#800   Snicker! You even sound like a paid promoter! Neverending 06/14/18 07:59:45 PM
#799   Every prediction you've made about IME has been SO75 06/14/18 07:47:47 PM
#798   Even the OTCQB is known as JUNK. You Neverending 06/14/18 07:46:14 PM
#797   Ok you go with what you know. Thanks SO75 06/14/18 07:45:12 PM
#796   Paid promoters are known to show up on Neverending 06/14/18 07:39:45 PM
#795   They trade on the pink sheets. Pink sheets SO75 06/14/18 07:33:48 PM
#794   In the US trading on the "pink sheets" Neverending 06/14/18 07:32:34 PM
#792   I STRONGLY suspect paid promoters are posting here. Neverending 06/14/18 07:09:48 PM
PostSubject